Filing Flows

Filing Flows › Companies › Bio-Techne › Cash flow

Bio-Techne cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow$67.2M in Q1 FY27 · $308M over twelve months

Operating cash flow$73.1M
Capital spending−$5.9M
Free cash flow+$67.2M
Cash / net income2.6×
Cash conversion cycle214 days

Analysis

In Q1 FY27, Bio-Techne generated $73.1M of operating cash flow and spent $5.9M on capital projects, leaving free cash flow of $67.2M. That is $45.0M more than in Q1 FY26 ($22.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was $338M; the largest uses were other financing ($142M), dividends ($50.0M), capital spending ($29.4M); besides operations, cash came from shares issued ($93.3M), other investing ($6.7M); the cash balance rose by $205M.

Operating cash flow was $73.1M against net income of $28.3M — 2.6× profit, cash ran ahead of reported earnings. The largest differences: depreciation & amortization +$23.7M, payables +$14.3M, employee-related liabilities −$13.5M.

Its cash conversion cycle was 214 days (receivables 64 + inventory 176 − payables 26).

Free cash flow

Bio-Techne: free cash flow by quarterBio-Techne: free cash flow by quarter$77.5MQ2 FY25$31.0MQ3 FY25$93.3MQ4 FY25$22.2MQ1 FY26$76.5MQ2 FY26$77.6MQ3 FY26$86.9MQ4 FY26$67.2MQ1 FY27
Operating cash flow less capital spending.
Bio-Techne: operating cash flow against capital spendingBio-Techne: operating cash flow against capital spendingOperating cash flowCapital spending$84.3M$6.8MQ2 FY25$41.1M$10.1MQ3 FY25$98.2M$4.9MQ4 FY25$27.6M$5.4MQ1 FY26$82.4M$5.9MQ2 FY26$86.7M$9.1MQ3 FY26$95.4M$8.5MQ4 FY26$73.1M$5.9MQ1 FY27
Latest (Q1 FY27): Operating cash flow $73.1M, Capital spending $5.9M.

Capital allocation, year by year

Bio-Techne: where the cash came from (up) and went (down), by fiscal yearBio-Techne: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksDividendsFY22: Operating cash flow $325MFY22: Net borrowing −$85.5MFY22: Shares issued $77.2MFY22: Capital spending −$44.9MFY22: Buybacks −$161MFY22: Dividends −$50.2M$402MFY22FY23: Operating cash flow $254MFY23: Net borrowing $94.0MFY23: Shares issued $29.8MFY23: Capital spending −$38.2MFY23: Acquisitions −$101MFY23: Buybacks −$19.6MFY23: Dividends −$50.3M$378MFY23FY24: Operating cash flow $299MFY24: Net borrowing −$31.0MFY24: Shares issued $60.9MFY24: Capital spending −$62.9MFY24: Acquisitions −$170MFY24: Buybacks −$80.0MFY24: Dividends −$50.4M$360MFY24FY25: Operating cash flow $288MFY25: Net borrowing $27.0MFY25: Shares issued $51.7MFY25: Asset sales $2.4MFY25: Capital spending −$31.0MFY25: Buybacks −$276MFY25: Dividends −$50.4M$369MFY25FY26: Operating cash flow $292MFY26: Net borrowing −$146MFY26: Shares issued $80.6MFY26: Asset sales $4.6MFY26: Capital spending −$28.9MFY26: Buybacks −$41.7MFY26: Dividends −$49.9M$377MFY26
Over these 5 years operating cash flow totalled $1.5B; the largest uses were buybacks ($578M) and acquisitions ($271M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$350M
Debt$400M
Net debt$50.0M

Bio-Techne funds itself: free cash flow was $308M over the last twelve months, and $350M of cash and investments stands against $400M of debt.

Where the cash came from and went

Bio-Techne: sources (+) and uses (−) of cash, Q1 FY27Bio-Techne: sources (+) and uses (−) of cash, Q1 FY27Cash drawn (+) / kept (−)−$85.3MOperating cash flow$73.1MShares issued$36.2MDividends−$12.6MTaxes on employees’ shares−$7.2MCapital spending−$5.9MOther investing$2.0MExchange rates−$247K
Bio-Techne: sources (+) and uses (−) of cash, TTM to Q1 FY27Bio-Techne: sources (+) and uses (−) of cash, TTM to Q1 FY27Operating cash flow$338MCash drawn (+) / kept (−)−$205MOther financing−$142MShares issued$93.3MDividends−$50.0MCapital spending−$29.4MTaxes on employees’ shares−$10.1MOther investing$6.7MExchange rates−$1.3M

From profit to cash

Bio-Techne: net income to operating cash flow, Q1 FY27Bio-Techne: net income to operating cash flow, Q1 FY27Net income$28.3MDepreciation & amortization$23.7MStock-based pay$13.4MDeferred taxes$2.4MReceivables$13.3MInventory−$2.5MPayables$14.3MEmployee-related liabilities−$13.5MPrepaid and other assets−$1.5MIncome taxes payable−$3.2MOperating cash flow$73.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY276417626214
Q4 FY266116421205
Q3 FY265817722213
Q2 FY265718025212
Q1 FY266318326220
Q4 FY256414722188
Q3 FY256516829204
Q2 FY256816729206

Every quarter

QuarterOperating cash flowCapital spendingBuybacksDividendsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27$73.1M−$5.9M—−$12.6M—$36.2M−$85.3M$67.2M
Q4 FY26$95.4M−$8.5M−$41.7M−$12.5M—$22.4M−$54.9M$86.9M
Q3 FY26$86.7M−$9.1M—−$12.5M−$60.0M$30.0M−$36.9M$77.6M
Q2 FY26$82.4M−$5.9M—−$12.5M−$40.0M$4.7M−$27.9M$76.5M
Q1 FY26$27.6M−$5.4M−$24K−$12.4M−$46.0M$23.5M$17.2M$22.2M
Q4 FY25$98.2M−$4.9M−$100M−$12.4M$16.0M$6.2M−$21.5M$93.3M
Q3 FY25$41.1M−$10.1M−$100M−$12.6M$30.0M$14.9M$36.9M$31.0M
Q2 FY25$84.3M−$6.8M—−$12.7M—$5.5M$10.0M$77.5M

Bio-Techne: income statement and cash flow

Bio-Techne, Q1 FY27: revenue $300M (+5% year over year), operating margin 12.2%. The chart follows the revenue to costs, profit and cash.

Bio-Techne: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.